UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?

Special Report by Charlotte Yu
Jan.19.2024
UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Without tax (price) incentives and flavor differentiation compared to traditional cigarettes, there would be little motivation for people to quit smoking.

A backbench debate was held on Jan 18 in the UK Parliament as the tenth session of the Conference of the Parties to the Framework Convention on Tobacco Control (COP10) is scheduled to take place in Panama from February 5 to 10, and the UK will be sending a delegation.

 

The debate, initiated by Members of Parliament Andrew Lewer, Mr. Virendra Sharma, and Martyn Day, aimed to challenge the WHO's opposition to e-cigarettes, focusing on the regulation of e-cigarettes in the UK, the World Health Organization (WHO), and the differing stances of the organization and the UK government on e-cigarettes.

 

The WHO for a long time has been committed to controlling the use of tobacco and nicotine products, particularly e-cigarettes. According to reports from December 14, 2023, the organization emphasized the need for urgent action to control e-cigarettes, aiming to protect children and non-smokers while minimizing health risks to the public. The WHO pointed out that the nicotine present in e-cigarettes is highly addictive and harmful to health.

 

During the debate on Thursday, Member of Parliament Andrew Lewer argued against this perspective. He cited research from Cancer Research UK, stating that "it's not nicotine but the chemicals produced during the combustion of tobacco that cause lung cancer."

 

Based on this theoretical finding, MP Andrew Lewer throughout the debate addressed vaporized e-cigarettes as "tobacco harm reduction products," aligning with the broader direction of the UK government's tobacco control policy. He insisted on two central arguments. First, new tobacco products, including vaporized e-cigarettes, should not be subject to the same tax rates as traditional cigarettes. Second, flavored vaporized e-cigarettes should not be banned. He argued that without tax (price) incentives and flavor differentiation compared to traditional cigarettes, there would be little motivation for people to quit smoking.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Andrew Lewer, a member of parliament who spoke in the backbench debate on January 18th | Image source: 2FIRSTS

 

In addition to urging the UK delegation to maintain its stance on the smoking cessation role of e-cigarettes in international conferences, Andrew Lewer also questioned the entire WHO institution during the debate and raised the issue of whether the UK should review the scale of its donations to the organization. This is because the UK is currently one of the largest funders of the WHO, and there is a need to ensure that "taxpayers' money is well utilized."

 

Later in the debate, co-initiator Virendra Sharma stated, "COP10 and WHO should not make it harder for those who want to quit smoking with e-cigarettes." Therefore, policies that excessively regulate e-cigarettes, heated tobacco, and oral nicotine pouches are worthy of debate.

 

He also mentioned that although the UK is a global leader in tobacco harm reduction policies, it can still learn from other countries' successful experiences in using new nicotine products to control smoking. He cited Japan and Sweden as examples where heated tobacco and oral snus significantly reduced smoking rates. There are better ways for the UK to achieve a better outcome through compromise.

 

Labour politician and Member of Parliament for Bristol South, Karin Marguerite Smyth, also participated in the debate. After expressing anticipation for the UK delegation's participation in the treaty conference and conveying the country's voice, she mentioned that many MPs have received letters from constituents inquiring about e-cigarettes and smoking because it will be a central topic at COP10. Voters are concerned about whether this conference will change the future use of e-cigarettes by British citizens. She asked the Minister of Public Health if there are plans to include other nicotine products in the upcoming government bill's regulatory process.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Virendra Sharma | Image source: 2FIRSTS

 

The responsibility of responding to inquiries in this debate fell on Dame Andrea Jacqueline Leadsom, who has taken office as the Deputy Minister of Public Health, Start for Life, and Primary Care since November 2023. She expressed opposing views to some points raised by the aforementioned MPs.

 

Using her own experience of teenage smoking and the challenging process of quitting, she stated that claiming nicotine is entirely harmless is "wrong" and reiterated the addictive nature of nicotine. She also raised some questions, mentioning that flavors like cherryade and bubble-gum are not designed for adults. These flavors and packaging resembling little Coke bottles or brightly colored like bubble-gum are clearly "aimed at children." The fact that e-cigarettes are placed next to candies, sold conveniently at pocket-money prices is concerning. Therefore, she urged MPs not to "naively look at this issue" and emphasized that only strong enforcement measures can ensure that e-cigarettes are not sold to minors.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Dame Andrea Jacqueline Leadsom who spoke in the back seat debate on January 18th | Image source: 2FIRSTS

 

Regarding the upcoming COP10, she described the UK as a "unique case" on the issue of e-cigarettes and stated that the country will present its position at the conference, emphasizing that e-cigarettes are a crucial tool to help adults quit smoking. "But as for whether there should be a change in the current level of donations to the WHO, the UK government tends to maintain the existing level." She concluded by stating that she will provide a statement to the Parliament after COP10 to update on the proceedings.

 

E-cigarettes in Backbench Debates

 

This is not the first time tobacco (or novel tobacco) has appeared in backbench debates in the UK.

 

Backbench debates, also known as Westminster Hall debates, allow MPs to raise local or national issues and receive responses from government ministers.

 

According to incomplete statistics, in June 2020, government MPs revolted against the ban on people importing liquid nicotine for e-cigarettes; on November 3, 2022, the House of Commons debated the Independent Review of Smokefree 2030 policies; and earlier this week, there was another debate on e-cigarettes. On January 16, a debate hosted by Conservative MP Peter Gibson discussed issues related to illicit (gray) market vaping products and underage illegal vaping.

 

The UK's stance on novel tobacco, especially e-cigarettes, has consistently differed from the WHO's perspective. The UK government has been supportive of e-cigarettes as an alternative to reduce the harm of smoking. According to the UK government's viewpoint, e-cigarettes can help smokers quit, and their harm is much lower than that of traditional tobacco products.

 

A report from Policy Exchange indicates that smoking has a significant impact on the economy, and reducing smoking rates not only improves health conditions and alleviates the burden on the national health service but also promotes productivity and economic growth.

 

2FIRSTS will continue to monitor the upcoming Conference of the Parties to the WHO Framework Convention on Tobacco Control (COP10) in Panama, as well as developments in UK tobacco control policies and regulations for both traditional and novel tobacco products.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
A U.S. Customs and Border Protection proposal to collect foreign export declarations and other overseas customs documents could expose discrepancies in the value, classification and description of China-made vape shipments entering the United States. A veteran Chinese logistics professional told 2Firsts that the measure, if implemented, could undermine the all-inclusive shipping model used by some unauthorized vape exporters and push parts of the trade toward costlier underground channels. The risk extends beyond higher duties: accurately declared products may also be more readily identified as unauthorized e-cigarettes subject to FDA enforcement.
Special Report
Sep.07
Ireland’s Vape Tax Raises €22 Million in Nine Months as Government Considers 2027 Budget Changes
Ireland’s Vape Tax Raises €22 Million in Nine Months as Government Considers 2027 Budget Changes
According to Irish media outlets Highland Radio and BreakingNews.ie, the Irish government is considering whether to adjust vape tax policy in the 2027 Budget. The tax has generated about €22 million ($24 million) in revenue during its first nine months. While no increase has been confirmed, the revenue performance could influence future fiscal discussions. Any tax rise could increase product costs and potentially affect retail prices.
Aug.12
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28
French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
Kumulus Vape, Europe’s first publicly listed vape company, reported a 7.8% year-on-year decline in first-half 2026 revenue. Amid changing conditions in France’s vape market, the company said channel diversification helped offset pressure, with physical store sales increasing 41.5% year on year. Listed on Euronext Access Paris in 2019 and later transferred to Euronext Growth Paris, Kumulus Vape is viewed as a representative company of Europe’s vape sector. Its performance highlights the industry’s shift from rapid expansion toward more operationally focused growth.
Jul.27
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10